Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Special Procedure Medications Each of these drugs requires a special procedure in order to dispense. Whenever there is a new patient coming in with one of these medications, be aware that action needs to be taken ASAP. Some require the physician and patient to be registered in a monitoring program. Some cannot be dispensed by a pharmacy. Accutane (isotretinoin) Used for treatment of severe acne that has not been helped by other treatments. Patient, physician and pharmacy must be registered with ipledge due to the teratogenic risk. Dispense a maximum of a one month supply, with no refills and must be dispensed within 7 days of date on yellow qualification sticker. The prescription must have this yellow Accutane Qualification Sticker verifying that the patient and physician have taken necessary precautions (two negative pregnancy tests before each written prescription, two forms of contraception, etc) Contact: www.ipledgeprogram.com or 1-866495-0654 Ampyra (dalfampridine) Indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. Physician and patient must complete the enrollment form. The physician’s office faxes the completed enrollment form to Ampyra Patient Support Services. Ampyra Patient Support Services confirms the patient’s insurance and eligibility for co-pay mitigation and forwards the prescription to a specialty pharmacy. The pharmacy will coordinate the deliveries of Ampyra with the patient. Contact: Ampyra Patient Support Services at 1-888-881-1918 (phone) or 1-888-883-3053 (fax). Avandia (Rosiglitazone) Indicated for the treatment of non-insulin dependent Type 2 diabetes mellitus. Includes rosiglitazone-containing medications: Avandamet, Avandaryl. Prescriber and patient must enroll in a special program. Dispensing of these medications will be limited to mail order through ONLY 3 specialty pharmacies: Medco, Accredo Wholesale and McKesson-Walgreens. Physician and patient must be registered in the REMS program. Enrollment forms are available online at: https://www.avandia.com/ Contact: Sanofi-Aventis at 1-800-AVANDIA (1-800-282-6342). Caprelsa (Vandetanib) a kinase inhibitor, is for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use of CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of CAPRELSA. To prescribe CAPRELSA® (vandetanib) Tablets, you must enroll in the CAPRELSA REMS Program and complete the prescriber training program. AstraZeneca will regularly evaluate compliance and reserves the right to contact you from time to time as a requirement of the CAPRELSA REMS Program. Certification in the CAPRELSA REMS Program requires 3 steps: 1. Review the HCP Education Pamphlet or HCP REMS Educational Slide Set Last Updated: July 26, 2012 1 and the CAPRELSA full Prescribing Information . Complete the prescriber training program. Registration with biologics 1 800 4306 Contact: www.caprelsarems.com 1877893 1510 Clozapine (Clozaril, Fazclo) Indicated for treatment of severely ill patients with schizophrenia who fail to respond to standard drug therapy or who are at risk of re-experiencing suicidal behavior. Available to enrolled health care practitioners and pharmacies only. Can be dispensed ONLY to registered patients with valid patient registration numbers, a WBC count and ANC report within the requirements of the clozapine product labeling WITHIN 7 DAYS OF DISPENSING, and a prescription from an enrolled health care practitioner. Patient must be assigned to a treating health care practitioner and dispensing pharmacy. Contact : www.clozapineregistry.com, www.clozarilcare.com, www.fazacloregistry.com Entereg (Alivmopan) ENTEREG is the first and only FDA-approved agent indicated to accelerate the time to upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis WARNING: FOR SHORT-TERM HOSPITAL USE ONLY ENTEREG is available only for short-term (15 doses) use in hospitalized patients. Only hospitals that have registered in and met all of the requirements for the ENTEREG Access Support & Education (E.A.S.E.™) Program may use ENTEREG. Contact info: http://www.entereg.com/ To get Product Pharmacy must be registered with REMS 1(800)278-0340 ExJade (deferasirox) Indicated for treatment of chronic iron overload due to blood transfusions. Physician must assist patient in enrolling in the EPASS system (Exjade Patient Assistance and Support Services) EPASS ensures that prescriptions are distributed via national specialty pharmacies, which review reimbursement benefits and organize delivery of EXJADE to a patient's home or location of choice. In addition, the specialty pharmacy will: o Call to confirm receipt of EXJADE and answer any questions o Call to remind your patients to refill prescription o EPASS Complete Care provides ONGOING patient SUPPORT Contact: 1-888-903-7277 (phone), 1-888-891-4924 (fax), or email at www.epassrx.com Increlex (mecasermin) Liquid containing man-made IGF-1 used to treat children who are very short for their age because they do not make enough IGF-1. Physician and patient must complete an SMN form (statement of medical necessity), with supporting documentation and a copy of the patient’s insurance card. Patient must also sign a “patient authorization to use/disclose health information” form. Distribution Program: The manufacturer established the TerciCare program to facilitate the prescribing, dispensing, and reimbursement processes. Increlex is only available through specialty pharmacies working with the manufacturer. Increlex is currently dispensed through 4 specialty pharmacies: Accredo, Caremark, CuraScript, and PharmaCare Contact: 1-866-837-2422 option #3; or www.tercica.com Iressa (gefitinib) Used for non-small cell lung cancer No new patients will be allowed to have access to IRESSA unless they are enrolled into a clinical trial approved prior to June.17th, 2005. IRESSA will only be obtainable through the IRRESA Access Program by approved patients. Last Updated: July 26, 2012 2 After September 15, 2005 pharmacies should not fill any prescription for IRESSA. After this date, please refer any patient with an IRESSA prescription to the IRESSA Access Program for assistance. The toll free number is: 1-800-601-8933. Patients can also be referred to AstraZeneca for assistance at 1-800-601-8933 Pharmacies cannot enroll patients into the IRESSA Access Program due to the patient and physician consent/certification forms that are required by the program. Letairis® (ambrisentan) to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs. LETAIRIS can improve your ability to exercise and it can help slow down the worsening of your physical condition and symptoms. BOXED WARNING Because of the risk of birth defects LETAIRIS is available only through a restricted program called the LETAIRIS Education and Access Program (LEAP). To receive LETAIRIS, you must talk to your doctor, understand the benefits and risks of LETAIRIS, and agree to all of the instructions in the LEAP program serious birth defects: LETAIRIS can cause serious birth defects if taken during pregnancy. Women must not be pregnant when they start taking LETAIRIS or become pregnant during treatment. Contact: http://www.letairis.com/patients/default.asp : (650) 574-3000 Lotronex (alosetron) Indicated ONLY for women with severe irritable bowel syndrome whose main problem is diarrhea and who did not get the relief needed from other treatments. Can be ordered by MedWorld Pharmacists need to: o Dispense only prescriptions that have a Prescribing Program Sticker - never fill telephone, facsimile, or computer-generated prescriptions; refills are permitted on written prescriptions o Dispense a Retail Pack for LOTRONEX, which includes Medication Guide, Prescribing Information, Medicine, and Follow-Up Survey Form o Encourage your patients who are prescribed LOTRONEX to enroll in Follow-Up Survey Contact: 1-888-825-5249 or www.lotronex.com LUMIZYME (alglucosidase alfa) – is used to treat a glycogen storage disorder called Pompe disease Lumizyme is only available through a restricted distribution program called the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program®. Before placing an order, physicians and healthcare facilities must complete training and enroll in the program. Prescribers must ensure that patients are enrolled in the program. Genzyme cannot authorize Lumizyme for shipment until all involved parties meet all program requirements, which must be re-verified for each shipment Contact 800-745-4447 Mifeprex (mifepristone) Indicated for termination of pregnancy in patients who are ≤49 days pregnant, dated from the first day of their last menstrual period. Physician must enroll in program to order this medication. Physician and patient must sign a Patient agreement form and physician must set up a follow-up visit at approximately 14 days to confirm complete termination of pregnancy. Mifeprex will be supplied only to licensed physicians who sign and return a Prescriber’s Agreement. Distribution of Mifeprex will be subject to specific requirements imposed by Last Updated: July 26, 2012 3 the distributor, including procedures for storage, dosage tracking, damaged product returns and other matters. Mifeprex is sold directly to approved physicians and is NOT AVAILABLE IN PHARMACIES Contact: 1-877-4-EARLY OPTION www.earlyoptionpill.com Nexavar (sorafenib) Indicated for treatment of advanced renal cell carcinoma. Physician must enroll patient in the REACH program (resources for expert assistance and care helpline). Physician and patient must sign declaration form and fax it to 1-866-6395181. After verifying the patient's insurance coverage, the REACH Program Counselor will send their prescription to a specialty pharmacy provider (SPP). The SPP will fill their prescription and arrange for delivery of Nexavar to them. Before each refill is due, they will receive a call to arrange the next delivery. Nexavar will not be filled through retail pharmacies, but can be supplied through the Omnicare ACS Special Pharmacy (1-855-488-2550), contact your Med World Pharmacist to order or get more information For more information contact Onyx at 1-866-639-2827 or www.NEXAVAR.com Propulsid (cisapride) Treatment of noturnal symptoms of gastroesophageal reflux disease (GERD); has demonstrated effectiveness for gastroparesis, refractory constipation, and nonulcer dyspepsia Withdrawn from the market due to fatal arrhythmias Avilable only through an investigational limited access program for specific conditions (gastroparesis, severe chronic constipation, and feeding intolerance in neonates. Patients must also meet the strict enrollment criteria. Institutions board review approval, completed FDA 1572 form and signed informed consent . To get more information on enrolling the pharmacy and procedures involved visit www.propulsid-lap.com or call 1-877-795-4247 Revlimid (lenalidomide) Indicated for myelodysplastic syndromes or multiple myeloma Revlimid can ONLY be prescribed by healthcare providers who are registered in the RevAssist program, dispensed by a pharmacy that is registered in the RevAssist program, and given to patients who are registered in the RevAssist program and who agree to do everything required in the program. Can be ordered through Omnicare ACS Special Pharmacy (1-855-488-2550), contact your Med World Pharmacist to order or get more information. For more information contact Celgene at 1-888-423-5436 or www.revlimid.com Sabril (Vigabatrin) This is an anticonvulsant indicated for infantile spasms, refractory complex partial seizures not controlled by conventional treatments. Only available through the Support, Help and Resources for Epilepsy (SHARE) program. The physician and patient need to be registered with the program in order to prescribe and dispense Sabril. This med can only be given to patients enrolled in and meet all conditions of SHARE. All initial prescriptions for Sabril must go through the SHARE Call Center (1-888-45SHARE [1-888-457-4273]) and will then be fulfilled by a specialty pharmacy Last Updated: July 26, 2012 4 Sabril is not available at retail pharmacies. Sabril is only available through 4 select specialty pharmacies (Accredo, Curascript, Pharmacare, and Caremark) as of 2/24/10 Forms available at http://www.lundbeckshare.com/pg512_important_steps.aspx . Contact SHARE at 1-888-45-SHARE. Soliris (Eculizumab) Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Atypical Hemolytic Uremic Syndrome (aHUS) and for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris, may become rapidly life-threatening or fatal if not recognized and treated early. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying therapy outweigh the risks of infection. Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected. Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) Can be ordered through Omnicare ACS Special Pharmacy (1-855-488-2550), contact your Med World Pharmacist to order or get more information. For more information contact the maker of Soliris at 1-888-SOLIRIS (1-888765-4747) Sucraid (sacrosidase) oral solution is an enzyme replacement therapy for use in the treatment of Congenital Sucrase-Isomaltase Deficiency (CSID) developed initially by Orphan Medical, Inc. CSID is a condition where your body lacks the enzymes needed to properly break down and absorb sucrose (table sugar) and isomaltase (a type of starch) from the intestines. It is important that licensed healthcare providers use the Sucraid® Patient Enrollment Form for new patients on therapy to ensure initial patient access and an uninterrupted supply of therapy as prescribed. Please complete the Sucraid® Patient Enrollment Form online, then print, sign (both patient and physician signature is required), and fax to 1866-777-7097. You can also scan the completed form and email it to [email protected]. This form provides all of the information required by the exclusive specialty pharmacy provider to arrange for patient access to Sucraid® Oral Solution. Can be stocked in pharmacy Contact: Phone: 1-866-469-3773 Fax: 772-365-3375 Email: [email protected] Suboxone, Subutex (buprenorphine) Used for maintenance and detoxification treatment in opioid addicted patients. Registration as Narcotic Treatment Program (NTP) is no longer required for prescribing/dispensing drugs for maintenance and detox therapies. ONDCPRA modified the restriction on the number of patients a physician is authorized to treat under the drug Addiction Treatment Act of 2000 (DATA 2000) Contact: 866-BUP-CSAT (866-287-2728) or email at [email protected] Last Updated: July 26, 2012 5 Thalomid (thalidomide) Indicated for treatment of patients with newly diagnosed multiple myeloma and for the acute treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum. Required Registration of Prescribers, Patients, and Pharmacies o All prescribers, patients, and pharmacies are required to register in the S.T.E.P.S.® program in order to prescribe, receive, or dispense Thalomid®. o Physician registration requires a DEA# or Social Security Number as well as the designation of a S.T.E.P.S.® coordinator for that prescriber (this may be the prescriber). The registration form is faxed to the prescriber and when completed faxed back to Celgene Corporation. o A pharmacy registers by having a designated pharmacist complete a similar registration form that is returned to Celgene. Authorization Validation o After the risk group appropriate patient acknowledgement / informed consent form has been completed and faxed to Celgene Corporation the patient is then instructed to complete the patient phone survey while the prescriber completes the physician phone survey. o Upon completion of the survey, the physician obtains an authorization number that is placed on the prescription which the patient then presents to the pharmacist. WITHOUT THE AUTHORIZATION NUMBER, THALOMID® CANNOT BE DISPENSED. Limiting Prescriptions to a 28-day Supply o Thalomid® prescriptions are limited to a duration of 28-days to allow for appropriate interval follow-up. Telephone prescriptions are not permitted. A new prescription is required for further dispensing (i.e. automatic refills are not permitted). To reflect the temporal restriction with regard to recent pregnancy testing, Thalomid® prescriptions are required to be filled WITHIN SEVEN DAYS of issue. Distribution of Thalomid® from Celgene to Registered Pharmacies o Thalomid® is directly shipped from Celgene to registered pharmacies. This allows Celgene to compare the amount of Thalomid® shipped to pharmacies with the amount of Thalomid® that specific pharmacies have been authorized to dispense. Can be ordered through Omnicare ACS Special Pharmacy (1-866-681-7131), contact your Med World Pharmacist to order or get more information. For more information contact the makers of Thalomid at:1-888-423-5436 Tikosyn (dofetilide) Indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/flutter of greater than one week duration who have been converted to normal sinus rhythm. Reserved for highly symptomatic patients. Physician must sign a TIKOSYN education program enrollment form to ensure that only prescribers who received appropriate education on treatment initiation and dosing guidelines can initiate TIKOSYN in a hospital setting and/or write prescriptions for this drug. T.I.P.S.™ stands for TIKOSYN In Pharmacy System. The T.I.P.S. program is designed to allow retail pharmacies to stock and dispense TIKOSYN once they have been enrolled. A retail pharmacy can enroll in the T.I.P.S. program by Completing and submitting the Last Updated: July 26, 2012 6 online T.I.P.S. Enrollment Form and ordering a T.I.P.S. Information Kit. Call 1-877TIKOSYN (845-6796) to request a T.I.P.S. Enrollment and Information Kit. MEDWORLD IS ENROLLED IN THE T.I.P.S. PROGRAM. Therefore, the pharmacy acknowledges receipt of the T.I.P.S. program materials and that the appropriate staff in the pharmacy are aware that for each outpatient prescription for TIKOSYN: o The pharmacist will verify that a prescriber has participated in the TIKOSYN Education Distribution Program and is confirmed in the TIKOSYN database before dispensing by checking the database via the Interactive Voice Response (IVR) telephone number, 1-800-788-7353, or the Web site, http://www.tikosynlist.com/. o The pharmacist will stamp each prescription for distribution with the T.I.P.S.™ stamp, verifying that the prescriber is a confirmed participant in the TIKOSYN Education Distribution Program. The pharmacist will then initial and date the stamped prescription in the appropriate areas. (stamp is kept in the IV department) o A copy of the above information is posted or otherwise made available to pharmacy staff to ensure that the staff understands these special conditions for use of TIKOSYN. The PharmaCare Specialty Pharmacy mail-order program will continue to be available to patients who prefer to receive their medication through PharmaCare. Upon patient discharge, PharmaCare requires the pharmacy enrollment form be completed and faxed along with the prescription, to PharmaCare Specialty Pharmacy. Contact: 1-877-TIKOSYN Tracleer (bosentan) Indicated for treatment of pulmonary arterial hypertension Because of the risks associated with treatment, the use of Tracleer requires participation in the Tracleer Access Program (T.A.P.), a restricted distribution program. TRACLEER IS NOT AVAILABLE IN A RETAIL PHARMACY. Contact: 1-866-228-3546 Tysabri (natalizumab) Indicated for patients with relapsing forms of MS and is available as a 1hr IV slow drip infusion TYSABRI is available only under a special restricted distribution program called the TOUCH® Prescribing Program. Under the TOUCH® Prescribing Program, only prescribers, infusion centers, and pharmacies associated with infusion centers registered with the program are able to prescribe, distribute, or infuse the product. Currently, 11 pharmacies nationally participate. For prescribers and patients, the TOUCH® Prescribing Program has two components: MS TOUCH® (for patients with multiple sclerosis) and CD TOUCH® (for patients with Crohn's disease). TYSABRI must be administered only to patients who are enrolled in and meet all the conditions of the MS or CD TOUCH® Prescribing Program. Contact the TOUCH® Prescribing Program at 1-800-456-2255 Contact: www.TYSABRI.com Ventavis (Iloprost) Ventavis is used for severe pulmonary arterial hypertension (PAH). Some of the side effects include feeling dizzy, lightheaded, and faint. The most common side effects of Ventavis include red face (flushing), increased cough, low blood pressure, headaches, nausea, spasm of your jaw muscles that makes it hard to open your mouth, and fainting. Last Updated: July 26, 2012 7 This is distributed through a specialty pharmacy. It is taken with a special nebulizer device-the I-neb AAD. For more information 1-866-228-3546 (1-866-ACTELION) Vivitrol (naltrexone) Indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with Vivitrol. Physicians, patients and providers must complete the VIP program enrollment form and submit it via fax or phone. AVAILABLE ONLY THROUGH 4 SPECIALTY PHARMACIES HANDLING VIVITROL IM (Caremark, Coram, Pharmacare, and Curascript) Contact: 1-800-848-4876 (phone) or 1-877-329-8484 (fax) Xenazine (tetrabenzine) Indicated for the treatment of chorea (brief, repetitive, jerky, or dancelike uncontrolled movements caused by muscle contractions) associated with Huntington’s disease. Xenazine requires a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits outweigh the risks. Xenazine has a black box warning for depression and suicidality. Xenazine is AVAILABLE ONLY THROUGH SPECIALTY PHARMACIES because of factors that relate to its orphan drug status and the need to provide appropriate education on the Risk Evaluation & Mitigation Strategy (REMS) program. Physician and patient fill out Xenazine Treatment Form and fax back to Xenazine Information Center. The medication is housed at 3 specialty pharmacies nationally and is either mailed directly to the patient or to the prescriber’s office, as requested on the treatment form. Monitoring and follow up is done by physician and adverse effects reported to the center. Can be ordered through Omnicare ACS Special Pharmacy (1-855-488-2550), contact your Med World Pharmacist to order or get more information. For more information contact the makers at: 1 888 882 6013, www.xenazineusa.com/healthcareprofessionals/prescribingxenazine/ Xyrem (sodium oxybate) Indicated for treatment of patients with narcolepsy who experience episodes of cataplexy, weak or paralyzed muscles. XYREM is a controlled substance (CIII). The active ingredient of XYREM is a form of GHB and has been a target for persons who abuse drugs and should be regulated as such. Patient and physician must be enrolled in Xyrem Risk Management Program. Medication is housed in a single centrallized pharmacy rather than a traditional retail pharmacy. Physician must see patient at least every 3 months. ALL XYREM PRESCRIPTIONS ARE FILLED BY A CENTRAL, MAIL ORDER PHARMACY. Contact: 1-866-XYREM-88 Zyprexa Relprevv This is a long acting atypical antipsychotic injectable medication. This med is restricted because of post injection delirium sedation syndrome (PDSS) which is severe drowsiness (including coma) and/or confusion and disorientation after each injection and must be observed at the doctor’s office or clinic for at least 3 hours after the injection is given. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ZYPREXA RELPREVV is not approved for the treatment of patients with dementia-related psychosis. Last Updated: July 26, 2012 8 Only prescribers and pharmacies registered with the program and prescribe and dispense this med. Med World pharmacy is not registered in the program. Zytiga (abiraterone) Use in combination with prednisone for patient with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel. Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, adrenocortical insufficiency, and hepatotoxicity. Can be ordered through Omnicare ACS Special Pharmacy (1-855-488-2550), contact your Med World Pharmacist to order or get more information. For the Janssen Support line contact 1-855 ZYTIGA Last Updated: July 26, 2012 9